Featured Research

from universities, journals, and other organizations

Outcomes improved by longer delays between heart attacks and elective surgeries, study finds

Date:
March 28, 2011
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
Recent heart attack patients should wait longer than currently recommended before undergoing elective surgery, a new study suggests.

Before undergoing elective surgery, patients should consider waiting longer after a heart attack than is currently recommended, according to a study scheduled for publication in the May issue of the journal Annals of Surgery.

The American Heart Association and the American College of Cardiology recommend patients wait at least four to six weeks after a heart attack before undergoing elective surgery. This guidance is based on studies conducted in the 1970s and 1980s.

The new study examined surgical outcomes among more than 550,000 California patients over a five-year period (1999-2004) who underwent five common elective surgeries after a heart attack. Researchers found substantially lower death rates and fewer subsequent heart attacks in those who waited eight or more weeks after a heart attack to undergo hip surgery, gallbladder removal, non-traumatic amputation, colon resection or elective abdominal aortic aneurysm repair.

"Despite medical advancements in the treatment of coronary artery disease today, a recent heart attack remains a very important risk factor for patients undergoing surgery," said Christian de Virgilio, MD, the study's corresponding author and a principal investigator at Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Our study suggests that patients should wait at least eight weeks after a heart attack before undergoing elective surgery. The results of the study also reignite the question of whether, in this high risk group, physicians should consider coronary artery stenting or bypass prior to elective surgery."

Researchers found the risk of subsequent heart attacks and death generally declined the longer the time between a heart attack and elective surgery. For instance, the risk of death for heart attack in patients undergoing hip surgery declined nearly 40 percent when the surgery took place more than six months after the heart attack.

Among patients who underwent hip surgery within 30 days of a heart attack, the study found 13.1 percent died within a month. Among those whose hip surgery occurred six months to one year after a heart attack, researchers found the death rate within a month was 7.9 percent. The risk of a subsequent heart attack went from 38.4 percent for hip surgery performed within a month of a heart attack to 6.2 percent for hip surgery performed six months to a year after a heart attack.

"Our research examined a much wider range of patients and surgeries than in past studies, and it points out the importance of a recent heart attack in determining the timing for elective surgeries," said Dr. de Virgilio.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Masha Livhits, Clifford Y. Ko, Michael J. Leonardi, David S. Zingmond, Melinda Maggard Gibbons, Christian de Virgilio. Risk of Surgery Following Recent Myocardial Infarction. Annals of Surgery, 2011; DOI: 10.1097/SLA.0b013e3182125196

Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Outcomes improved by longer delays between heart attacks and elective surgeries, study finds." ScienceDaily. ScienceDaily, 28 March 2011. <www.sciencedaily.com/releases/2011/03/110324103126.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2011, March 28). Outcomes improved by longer delays between heart attacks and elective surgeries, study finds. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/03/110324103126.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Outcomes improved by longer delays between heart attacks and elective surgeries, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/03/110324103126.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins